Retatrutide: Known vs Unknown
Source index- Triple agonist mechanism (GIP, GLP-1, glucagon receptor activation) confirmed in preclinical and Phase 1/2 data Source: Jastreboff et al., NEJM 2023 — Phase 2 dose-ranging trial, n=338
- Dose-dependent weight reduction observed across all Phase 2 cohorts in trial population Source: NCT04881760 — 24-week primary endpoint data, published 2023
- GI side-effect profile (nausea, vomiting) consistent with GLP-1 class; no new safety signals in Phase 2 Source: Eli Lilly Phase 2 safety data, NEJM 2023 supplementary appendix
- Phase 3 TRIUMPH program actively enrolling as of Q1 2026 Source: ClinicalTrials.gov NCT05882669 — status: Recruiting
- Long-term cardiovascular outcomes data (MACE endpoint study not yet initiated or reported) Phase 3 TRIUMPH-CV arm: design not yet published in public registries
- Safety and efficacy in specific populations: pediatric, renal impairment, hepatic impairment — no data Standard exclusion criteria apply in all published Phase 2 cohorts
- Drug-drug interaction profile at approved dose range: not yet characterized in available literature No published pharmacokinetic interaction studies identified as of Jun 2026
- Identity, purity, and stability of retatrutide sourced from research vendors: no independent verification at scale Third-party lab audit of vendor-supplied "reta" compounds: ongoing tracker project
Featured regulatory update
Full update logCompounding facilities and GLP analogues: what the 2026 FDA guidance shift means for reta research buyers
503B outsourcing facilities that previously compounded semaglutide under shortage provisions are facing new restrictions following FDA's shortage resolution declaration in late 2025. The regulatory trajectory for retatrutide — still unapproved and thus structurally different — requires separate analysis. We tracked the guidance documents and mapped the compounding-risk landscape for the current moment.
Vendors supplying compounded "retatrutide" operate entirely outside FDA-approval infrastructure. No compounded version of retatrutide has been reviewed or authorized by the FDA. This is distinct from the tirzepatide and semaglutide compounding situation, where shortage exemptions previously applied.
Vendor counterfeit risk
Risk methodologyKnown risk vectors for reta-labeled compounds
High-scrutiny category-
HighUnlinked or generic COA
The most common risk signal: a certificate of analysis that cannot be traced to a specific production batch. Any vendor supplying a PDF without a unique lot identifier and matching third-party lab name should be treated as unverified. In our audit, the majority of reta-labeled vendor COAs reviewed in 2025–26 failed this check.
-
HighMisrepresented compound identity
Retatrutide (LY3437943) is a large peptide with a specific amino acid sequence. HPLC purity tests alone do not confirm compound identity. Mass spectrometry or sequence-confirmed identity testing is required. Vendors offering only HPLC results cannot confirm the vial contains retatrutide specifically.
-
MediumStorage and reconstitution integrity claims
Peptide stability under shipping and storage conditions is a legitimate variable. Vendors making specific stability claims without supporting data introduce a medium-risk signal. Cold-chain documentation should be available on request from any serious research supplier.
-
LowerHuman-use marketing language on research product pages
Language implying clinical use, referencing personal regimens, or using outcome-oriented framing on a research-compound product page is an FDA compliance signal and a proxy indicator of overall vendor quality. Lower risk in isolation but often correlates with the above issues.
Update log
Full archiveTRIUMPH-1 site count expands to 47 clinical locations across US and EU
ClinicalTrials.gov record updated; enrollment remains open. No interim data or protocol amendments noted in the public record.
FDA confirms no approved indication for retatrutide in the human use database as of June 2026
Confirmed via Drugs@FDA search and Orange Book review. No NDA or BLA submissions on file for this compound.
New preprint: glucagon receptor contribution to retatrutide's mechanism under analysis
Unpeer-reviewed preprint posted on bioRxiv examines relative receptor contribution weighting. Not yet integrated into our evidence panel pending peer review.
Three vendors flagged for mass-spec gap on claimed retatrutide SKUs
COA review found purity certificates but no sequence-level identity confirmation. Risk rating for the "reta" category elevated to elevated as a result.
503B compounding facilities: FDA confirms GLP-class compounds require individual shortage exemption
Guidance clarification posted to FDA.gov. Retatrutide, being unapproved, is categorically outside shortage-exemption frameworks that apply to tirzepatide and semaglutide.
